To validate the pharmacological approach, we used a genetic strategy and treated R211 and PDAC8661 murine pancreatic tumour cells with pools of scramble siRNA, siRNA targeting p110α or mixed siRNA targeting each class I PI3K catalytic subunit, with the latter condition mimicking a pan‐PI3K inhibitor. Here, PIK3CG is linked to pancreatic neoplasm.